Matricelf (TASE: MTLF) announced the successful completion of its comprehensive GLP safety study for its engineered neural tissue implant, achieving all predefined study endpoints with no abnormal findings.
According to Matricelf, the GLP study was designed as an IND-enabling safety program and represents a significant milestone in Matricelf’s preparations for a first-in-human clinical trial in spinal cord injury patients.
In a statement, Gil Hakim, CEO of Matricelf, commented, “This achievement marks a major milestone for Matricelf and brings us one step closer to submitting an application for a first-in-human clinical trial. The results provide strong support for the safety profile of our technology and represent an important step toward translating our personalized neural tissue implant into a clinical treatment for spinal cord injury patients.”
